CompletedPhase 2psilocybin

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT ID

NCT05399498

Target Enrollment

9 participants

Start Date

2023-11-01

Est. Completion

2025-12-01

About This Study

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

Conditions Studied

Borderline Personality DisorderMajor Depressive Disorder

Interventions

•Psilocybin

Eligibility

Age:18 Years - 65 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Age 18-65
* Diagnosed with current major depressive disorder
* Montgomery-Asberg Depression Rating Scale (MADRS) score of \> 20
* Diagnosed with borderline personality disorder
* Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of \> 20
* Ability to understand and sign the consent form

Exclusion Criteria:

* Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
* Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
* Illegal substance use based on urine toxicology screening (except cannabis use)
* Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder
* Active substance use disorder

Study Locations (1)

University of Chicago

Chicago, Illinois, United States